P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC

The KEAP1/NRF2 pathway is mutationally activated in approximately 20-25% of NSCLC patients. NRF2 activation protects against oxidative stress and promotes tumor growth and survival. KEAP1/NRF2 mutations in advanced NSCLC are associated w/ dramatically shorter survival and poor outcomes following standard-of-care therapy. These tumors have heightened dependency on glutaminase-mediated conversion of glutamine to glutamate due to upregulation of...